Publication details

Agomelatin: nové antidepresivum s anxiolytickými účinky

Investor logo
Title in English Agomelatine: new antidepressant with anxiolytic effects

ŠULCOVÁ Alexandra

Year of publication 2011
Type Article in Periodical
Magazine / Source Psychiatrie pro praxi
MU Faculty or unit

Central European Institute of Technology

Field Pharmacology and pharmaceutical chemistry
Keywords agomelatine; antidepressant; anxiolytic.
Description A novel drug in the class of antidepressant agomelatine is unique in its pharmacological mechanisms of action. Initially it was investigated to treat circadian sleep disturbances due to its agonistic influence on the melatonergic (MT1 and MT2) receptors. Preclinical as well as clinical studies however demonstrated antidepressive effects of agomelatine what is believed to be associated with its combined pharmacological action that is a blockage at serotonin 5-HT2C receptors. Stimulation of these receptors is known to induce panic in man and anxiogenic-like effects in animals, while their blockage elicited anxiolytic action. Furthermore the anxiolytic effect of agomelatonine is not inhibited by co-administration of the selective blocker of melatonergic receptors S-22153. According to results of preclinical and recent clinical studies agomelatine is considered for suppression of anxious symptoms in depressed patients and for treatment of generalized anxiety disorder.
Related projects:

You are running an old browser version. We recommend updating your browser to its latest version.

More info